A U.S. court on Monday allowed Eli Lilly to continue advertising its weight-loss drugs, ruling against rival Novo Nordisk's claims that the ads were false and misleading. The decision permits Eli Lilly to proceed with its marketing campaigns for its weight-loss medications.
The ruling allows Eli Lilly to continue its marketing campaigns for its weight-loss drugs, potentially impacting market share and revenue for both Eli Lilly and Novo Nordisk in the competitive weight-loss drug market.
Every achievement starts with investmenthome.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
A U.S. court ruled on Monday that Eli Lilly can continue to advertise its weight-loss drugs. The decision came after rival Novo Nordisk had claimed that Eli Lilly's advertisements were false and misleading. The court's ruling permits Eli Lilly to proceed with its marketing efforts for its weight-loss medications.
Pick the topics you care about. Get only what matters, on your cadence.